Created this new thread to keep the Chart thread on-topic.
( see this post for background: https://hotcopper.com.au/posts/42690928/single )
From clinicaltrials.gov first patient was effectively enrolled 19 July 2019.
https://clinicaltrials.gov/ct2/show/NCT03820908?term=Bisantrene&draw=2&rank=1
Then we had ASX announcement 25 July 2019. Announcement occurred after completion of first 7-days of treatment (with no complications).
https://www.asx.com.au/asxpdf/20190725/pdf/446w20y5617czz.pdf
Reading the study design they first receive a 7-day course of Bisantrene,. There is also a 3-day consolidation treatment after Complete Response (optional).
@RaceOncology reading the two historic paediatric cases with long term survival I note one patient received a lower dose 5-day course at 200mg/m2/day and the other received a 7-day 250mg/m2/day course.
In the investigator-lead trial they are going for a longer 7-day course plus an additional optional 3-day consolidation course. That additional consolidation course is interesting ... seems to be like a booster measure to minimise risk of relapse.
Has the 3-day consolidation course been added due to specific findings from previous Phase II studies?
Progress of Israel R/R AML trial
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
-0.010(0.82%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.20 | $15.52K | 12.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6317 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 430 | 1 |
View Market Depth
| Last trade - 10.35am 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.21 |
Change
-0.010 ( 1.68 %) |
||||
| Open | High | Low | Volume | ||
| $1.22 | $1.25 | $1.20 | 5826 | ||
| Last updated 10.35am 08/05/2024 ? | |||||
| RAC (ASX) Chart |